Patents Assigned to SynLife, Inc.
  • Publication number: 20230364202
    Abstract: The present disclosure provides compositions of microparticles and uses thereof for removing toxic or undesirable molecules from an environment, e.g. the blood of a subject. The microparticles can be liposomes. In one embodiment, the aqueous phase of the liposomes contains (i) a system of generating NAD+ from NADH, and (ii) one or more enzymes that are involved in one or more NAD+-dependent reactions that remove the toxic or undesirable molecules from the environment. In one embodiment, the liposomes contain NADH oxidase, alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) to remove ethanol from the blood of a subject.
    Type: Application
    Filed: July 24, 2023
    Publication date: November 16, 2023
    Applicant: SynLife, Inc.
    Inventors: Felix MOSER, David BENJAMIN
  • Patent number: 11723958
    Abstract: The present disclosure provides compositions of microparticles and uses thereof for removing toxic or undesirable molecules from an environment, e.g. the blood of a subject. The microparticles can be liposomes. In one embodiment, the aqueous phase of the liposomes contains (i) a system of generating NAD+ from NADH, and (ii) one or more enzymes that are involved in one or more NAD+-dependent reactions that remove the toxic or undesirable molecules from the environment. In one embodiment, the liposomes contain NADH oxidase, alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) to remove ethanol from the blood of a subject.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 15, 2023
    Assignee: SYNLIFE, INC.
    Inventors: Felix Moser, David Benjamin
  • Publication number: 20220049269
    Abstract: Synthetic minimal cells (SMC) are provided for delivering a therapeutic or diagnostic agent to a subject or to a site within a subject in need of treatment or diagnosis. SMCs may be targeted to the site or sense the site and initiate production and release of the therapeutic or diagnostic agent. SMCs comprise a sensor, at least one genetic circuit and outputting means to deliver the therapeutic agent.
    Type: Application
    Filed: September 23, 2019
    Publication date: February 17, 2022
    Applicant: SynLife, Inc.
    Inventors: Felix MOSER, Katarzyna ADAMALA, David BENJAMIN, Edward Stuart BOYDEN, Jeremy WERTHEIMER, Kevin MUNNELLY, Elazer EDELMAN
  • Publication number: 20210213107
    Abstract: The present disclosure provides compositions of microparticles and uses thereof for removing toxic or undesirable molecules from an environment, e.g. the blood of a subject. The microparticles can be liposomes. In one embodiment, the aqueous phase of the liposomes contains (i) a system of generating NAD+ from NADH, and (ii) one or more enzymes that are involved in one or more NAD+-dependent reactions that remove the toxic or undesirable molecules from the environment. In one embodiment, the liposomes contain NADH oxidase, alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) to remove ethanol from the blood of a subject.
    Type: Application
    Filed: April 21, 2020
    Publication date: July 15, 2021
    Applicant: SynLife, Inc.
    Inventors: Felix MOSER, David BENJAMIN
  • Publication number: 20190309015
    Abstract: A general method is described for purifying any protein from a complex mixture by anchoring the protein of interest to liposomes that can be easily isolated from the complex mixture, then separated from the liposome and purified if desired.
    Type: Application
    Filed: April 8, 2019
    Publication date: October 10, 2019
    Applicant: SynLife, Inc.
    Inventor: Felix MOSER